Stifel has recently initiated Cullinan Therapeutics Inc (CGEM) stock to Buy rating, as announced on May 1, 2024, according to Finviz. Earlier, on April 15, 2024, William Blair had initiated the stock ...

Nicholas Cullinan, the new director of the British Museum, has announced a groundbreaking $1.3 billion transformation plan, ...

In an effort to control the development of a Downtown Peoria block, CIty Hall wants to buy two buildings and a parking deck ...

Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic ...

BTIG analyst Julian Harrison maintained a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target of ...

The Human Research Ethics Committee (HREC) in Australia has granted clearance for Cullinan Therapeutics to commence an ...

The newly-evolved Rolls-Royce Cullinan Series II appeals to the discerning tastes of ultra-luxury SUV enthusiasts through ...

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock ...

Sept. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today shared updated data in ...

Rolls-Royce has unveiled the Cullinan Series II, marking a bold evolution of its renowned super-luxury SUV. This latest ...

H.C. Wainwright has reaffirmed its positive stance on Cullinan Oncology Inc. (NASDAQ: CGEM), maintaining a Buy rating and a $28.00 price target for the company's stock. This endorsement follows ...

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic ...